This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Deckers, Allscripts: After-Hours Trading

NEW YORK ( TheStreet) -- Shares of Deckers Outdoor (DECK) were getting hammered in late trades on Thursday after the fashion footwear seller missed Wall Street's consensus profit view because of weakness in gross margins and lowered its full-year outlook.

The Goleta, Calif.-based company, whose brands include UGG boots and Teva scandals, earned $8 million, or 20 cents a share, on sales of $246.3 million in the first quarter, below the average estimate of analysts polled by Thomson Reuters for a profit of 25 cents on revenue of $246.5 million.

For the second quarter, Deckers sees year-over-year revenue growth of 8%, a loss per share of 60 cents a share and gross margin of 43%, a sequential decline from 46% in the latest quarter. The company lowered its view for fiscal 2012 to a year-over-year decrease of 9-10% in earnings per share from a prior view for a flat performance.



The stock was last quoted at $56.91, down 18%, on volume of more than 400,000, according to Nasdaq.com.

"Our first quarter performance was mixed versus our expectations," stated Angel Martinez, President, Chief Executive Officer and Chair of the Board of Directors. "Sales growth was driven by the addition of the Sanuk brand combined with increased demand for the UGG brand spring line, partially offset by softness in boots due to the unusually warm weather. The difference in the channel mix versus projections, along with some higher closeouts for the Teva brand and non-Classic UGG brand styles, put some additional pressure on overall gross margins on top of the higher product costs we had forecasted."

Deckers attributed its lower full-year outlook to the higher costs of goods sold and increasing levels of closeout sales.

Check out TheStreet's quote page for Deckers Outdoor for year-to-date share performance, analyst ratings, earnings estimates and much more.

Allscripts Health Solutions

Shares of Allscripts Health Solutions (MDRX) plunged late Thursday after the company's first-quarter results fell far short of Wall Street expectations because of weak sales, elevated software development expenses and an unfavorable sales mix.

The company reported non-GAAP earnings of 12 cents a share on revenue of $365.5 million for the March quarter. The average estimate of analysts polled by Thomson Reuters was for earnings of 24 cents a share on revenue of $387.7 million.

Allscripts also lowered its outlook, announced that Chief Financial Officer Bill Davis is leaving the company, and disclosed a shake-up of its board with Phil Pead being terminated as chairman and three other directors resigning.

The stock dropped 46% to $8.70 on after-hours volume of 5.3 million.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,071.22 -41.93 -0.24%
S&P 500 1,977.80 -5.05 -0.25%
NASDAQ 4,505.8520 -6.3420 -0.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs